Sagimet Biosciences Inc. (SGMT)
NASDAQ: SGMT
· Real-Time Price · USD
7.68
-0.99 (-11.42%)
At close: Aug 15, 2025, 3:59 PM
7.83
1.95%
After-hours: Aug 15, 2025, 07:47 PM EDT
Company Description
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways.
Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne.
The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers.
The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019.
Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Sagimet Biosciences Inc.

Country | United States |
IPO Date | Jul 17, 2023 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 14 |
CEO | David A. Happel |
Contact Details
Address: 155 Bovet Road San Mateo, California United States | |
Website | https://sagimet.com |
Stock Details
Ticker Symbol | SGMT |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001400118 |
CUSIP Number | 786700104 |
ISIN Number | US7867001049 |
Employer ID | 20-5991472 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
David A. Happel | Chief Executive Officer, President & Director |
Thierry Chauche | Chief Financial Officer & Principal Accounting Officer |
Dr. Eduardo Bruno Martins DPhil, M.D., Ph.D. | Chief Medical Officer |
Dr. Lucas Pelkmans Ph.D. | Co-Founder |
Dr. Marie O'Farrell Ph.D. | Senior Vice President of Research & Development |
Elizabeth Rozek Esq., J.D. | General Counsel & Chief Compliance Officer |
Robert D'Urso | Senior Vice President of New Products |
Urs Greber Ph.D. | Co-Founder |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Aug 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |
Aug 14, 2025 | 8-K | Current Report |
Aug 14, 2025 | 424B5 | Filing |
Aug 14, 2025 | SCHEDULE 13G | Filing |
Aug 13, 2025 | 8-K | Current Report |
Aug 13, 2025 | 10-Q | Quarterly Report |
Jul 23, 2025 | 4 | Filing |
Jul 23, 2025 | 4 | Filing |
Jul 23, 2025 | 4 | Filing |
Jun 24, 2025 | SCHEDULE 13G/A | [Amend] Filing |